Menu
Search
|

Menu

Close
X

ZIOPHARM Oncology Inc ZIOP.OQ (NASDAQ Stock Exchange Capital Market)

3.71 USD
-- (--)
As of Feb 22
chart
Previous Close 3.71
Open --
Volume --
3m Avg Volume 391,833
Today’s High --
Today’s Low --
52 Week High 7.88
52 Week Low 3.33
Shares Outstanding (mil) 141.96
Market Capitalization (mil) 526.68
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
5
FY16
7
FY15
4
EPS (USD)
FY17
-0.406
FY16
-1.322
FY15
-1.013
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
82.44
8.08
Price to Book (MRQ)
vs sector
--
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-52.34
13.67
Return on Equity (TTM)
vs sector
--
15.40

EXECUTIVE LEADERSHIP

Laurence Cooper
Chief Executive Officer, Since 2015
Salary: $500,000.00
Bonus: $700,000.00
Kevin Lafond
Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer, Since 2013
Salary: $245,000.00
Bonus: $51,450.00
David Mauney
Interim Chief Operating Officer, Executive Vice President, Chief Business Officer, Since 2017
Salary: --
Bonus: --
Francois Lebel
Executive Vice President - Research and Development and Chief Medical Officer, Since 2015
Salary: $410,000.00
Bonus: $114,800.00
Lynn Ferrucci
Senior Vice President - Human Resources, Facilities and Administration, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One First Avenue Parris Building
, Navy Yard Plaza
BOSTON   MA   02129

Phone: +1617.2591970

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

SPONSORED STORIES